South Side-based Carmell Therapeutics Corp. has begun trading as a public company after merging with a special purpose acquisition company in July.
Carmell, a Carnegie Mellon University spinout founded in 2007 and focusing on plasma-based biomaterials for active soft tissue repair and other applications, merged with Alpha Healthcare Acquisition Corp. III to form Carmell Therapeutics Corp. The company is trading on the Nasdaq stock exchange under the CTCXW and CTCX ticker symbols respectively.
Rajiv Shukla is Carmell’s executive chairman and Randy Hubbell is CEO of the combined company.
AHAC and Carmell inked a business combination agreement in January, which was later approved by stockholders at AHAC and Carmell. After reservation for certain tax obligations and satisfaction of redemption requests, the AHAC Trust regained gross proceeds of about $29.4 million.
Boston-based Goodwin Procter LLP provided legal counsel to AHAC; Troutman Pepper Hamilton Sanders LLP of Atlanta was legal counsel for Carmell.
Kris B. Mamula: kmamula@post-gazette.com





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.